Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
A phase I study to determine the maximum tolerable dose (MTD) and to evaluate
pharmacokinetic, safety/tolerability and efficacy profiles of antroquinonol (Hocena®) in
non-small cell lung cancer (NSCLC) subjects refractory to conventional treatment modalities